Just wondering if anyone (@mikebrisy @Nnyck777 @BendigoInvesto) had any comment on their latest update?

Thanks

C

Record DAYBUE™ net sales of US$101.1 million in Q3 2025, up 11%

from Q3 2024

Q3 Highlights:

from Q2 2025

• Q3 2025 DAYBUE™ (trofinetide) net sales of US$101.1 million, up 11% from Q3 2024 and up 5%

• For the first time more than 1,000 patients received shipments

• Largest quarter-over-quarter increase in referrals since launch driven by expanded team

• 74% of prescriptions to new patients were written by physicians in the community setting outside

centers of excellence

• Named patient supply programs active across multiple regions outside North America

• Neuren earned Q3 2025 royalty income of A$16.4 million, up 24% from Q3 2024 and up 12% from

Q2 2025

• Acadia narrowed full year 2025 DAYBUE US net sales guidance to US$385 – 400 million (previously

US$380 - 405 million), implying full year 2025 US royalty income for Neuren of A$63 – 66 million

(previously A$62 - 67 million)